2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2256-2269

  Squarcialupi, Lucia ^a   Colotta, Vittoria ^a   Catarzi, Daniela ^a   Varano, Flavia ^a   Filacchioni, Guido ^a   Varani, Katia ^b   Corciulo, Carmen ^b   Vincenzi, Fabrizio ^b   Borea, Pier Andrea ^b   Ghelardini, Carla ^c   Di Cesare Mannelli, Lorenzo ^c   Ciancetta, Antonella ^d   Moro, Stefano ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Dipartimento di Neuroscienze   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARYLPYRAZOLO(4,3 D)PYRIMIDIN 7 AMINO; ADENOSINE A3 RECEPTOR ANTAGONIST; AMINO ACID DERIVATIVE; CARBAMIC ACID DERIVATIVE; MOLECULAR SCAFFOLD; OXALIPLATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CLINICAL EVALUATION; COLON CANCER; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR BIOLOGY; NEUROTOXICITY;

ADENOSINE A3 RECEPTOR ANTAGONISTS; ANIMALS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PYRIMIDINES; RATS; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84875721987     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400068e     Document Type: Article

References (53)

1. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International union of Pharmacology XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 2001, 53, 527-552
2. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Linden, J.; Muller, C. E. International union of Pharmacology LXXXI. Nomenclature and classification of adenosine receptors. An up date Pharmacol. Rev. 2011, 63, 1-34
3. Jacobson, K. A.; Knutsen, L. J. S. P1 and P2 purine and pyrimidine receptor ligands. In Purinergic and Pyrimidinergic Signalling; Abbracchio, M. P.; Williams, M., Eds; Springer: Berlin, 2001; Handbook of Experimental Pharmacology, Vol. 151/1, pp 129-175.
4. 3 adenosine receptor: pharmacology and role in disease Handb. Exp. Pharmacol. 2009, 193, 297-327
5. 3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H279-H2801
6. Schulte, G.; Fredholm, B. B. Signalling from adenosine receptors to mitogen-activated protein kinases Cell. Signal. 2003, 15, 813-827
7. Gessi, S.; Merighi, S.; Sacchetto, V.; Simioni, C.; Borea, P. A. Adenosine receptors and cancer Biochim. Biophys. Acta 2011, 1808, 1400-1412
8. 3 adenosine receptor affect cell cycle progression and cell growth Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 225-234
9. 3 adenosine receptor: an enigmatic player in cell biology Pharmacol. Ther. 2008, 117, 123-140
10. Boison, D.; Chen, J.-F.; Fredholm, B. B. Adenosine signaling and function in glial cells Cell Death Differ. 2010, 17, 1071-1082
11. Liu, W.; Tang, Y.; Feung, J. Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system Life Sci. 2011, 89, 141-146
12. 3 adenosine receptor activation FASEB J. 2012, 26, 1855-1865
13. Pedata, F.; Pugliese, A. M.; Coppi, E.; Popoli, P.; Morelli, M.; Schwarzschild, M. A.; Melani, A. Adenosine in the central nervous system: effects on neurotransmission and neuroprotection Immun., Endoc. Metab. Agents Med. Chem. 2007, 7, 304-321
14. 3 receptor ligands: past, present and future trends Curr. Top. Med. Chem. 2010, 10, 942-975
15. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. 1,2,4-Triazolo[4,3-a]quinoxalin-1- one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists J. Med. Chem. 2000, 43, 1158-1164
16. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new sets of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists J. Med. Chem. 2000, 43, 3118-3124
17. 3 adenosine receptor antagonists: synthesis, pharmacological and ligand-receptor modeling studies J. Med. Chem. 2004, 47, 3580-3590
18. 3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives J. Med. Chem. 2005, 48, 7932-7945
19. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and and ligand-receptor modeling studies J. Med. Chem. 2006, 49, 3916-3925
20. 3 adenosine receptor antagonists: synthesis, pharmacological evaluation, and ligand-receptor modeling studies J. Med. Chem. 2007, 50, 4061-4074
21. 3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study J. Med. Chem. 2007, 50, 6596-6606
22. 3 Adenosine Receptor Antagonists Bioorg. Med. Chem. 2008, 16, 6086-6102
23. 3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies Bioorg. Med. Chem. 2009, 17, 401-410
24. Colotta, V.; Lenzi, O.; Catarzi, D.; Varano, F.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Ciampi, O.; Pugliese, A. M.; Traini, C.; Pedata, F.; Schiesaro, A.; Morizzo, E.; Moro, S. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a] pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Pharmacological evaluation, and ligand-receptor modeling studies J. Med. Chem. 2009, 52, 2407-2419
25. 3 Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition J. Med. Chem. 2009, 52, 7640-7652
26. 3 Adenosine Receptor Antagonists J. Med. Chem. 2011, 54, 2102-2113
27. Lenzi, O.; Colotta, V.; Catarzi, D.; Varano, F.; Squarcialupi, L.; Filacchioni, G.; Varani, K.; Vincenzi, F.; Borea, P. A.; Dal Ben, D.; Lambertucci, C.; Cristalli, G. Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4- c ]quinoline derivatives as adenosine receptor antagonists Bioorg. Med. Chem. 2011, 19, 3757-3768
28. McElvain, S. M.; Stevens, C. L. Ketene Acetals. XVI. Phenylketene Diethyl- and Dimethylacetals from the Pyrolysis of the Corresponding Orthoesters J. Am. Chem. Soc. 1946, 68, 1917-1921
29. 2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217
30. 2A adenosine receptor J. Biol. Chem. 1995, 270, 13987-13997
31. 3 adenosine receptor J. Biol. Chem. 2002, 277, 19056-19063
32. Galabov, A.; Galabov, B.; Neykova, N. Structure-Activity Relationship of Diphenylthiourea Antivirals J. Med. Chem. 1980, 23, 1048
33. Aschner, M.; Sonnewald, U.; Tan, K. H. Astrocyte modulation of neurotoxic injury Brain Pathol. 2002, 12, 475-481
34. Marchand, F.; Perretti, M.; McMahon, S. B. Role of the immune system in chronic pain Nat. Rev. Neurosci. 2005, 6, 521-532
35. Scholz, J.; Woolf, C. J. The neuropathic pain triad: neurons, immune cells and glia Nat. Neurosci. 2007, 10, 1361-1368
36. Gamelin, E.; Gamelin, L.; Bossi, L.; Quasthoff, S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures Semin. Oncol. 2002, 29, 21-33
37. Di Cesare Mannelli, L.; Zanardelli, M.; Failli, P.; Ghelardini, C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin J. Pain 2012, 13, 276-284
38. Elekes, O.; Venema, K.; Postema, F.; Dringen, R.; Hamprecht, B.; Korf, J. Evidence that stress activates glial lactate formation in vivo assessed with rat hippocampus lactography Neurosci. Lett. 1996, 208, 69-72
39. Milligan, E. D.; Watkins, L. R. Pathological and protective roles of glia in chronic pain Nat. Rev. Neurosci. 2009, 10, 23-36
40. Cavaletti, G.; Tredici, G.; Petruccioli, M. G.; Dondè, E.; Tredici, P.; Marmiroli, P.; Minoia, C.; Ronchi, A.; Bayssas, M.; Erienne, G. G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat Eur. J. Cancer 2001, 37, 2457-2463
41. MOE (Molecular Operating Environment), version 2010.10; Chemical Computing Group Inc.: Montreal, Quebec, Canada, 2010.
42. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relationships in G-protein coupled receptors Methods Neurosci. 1995, 25, 366-428
43. GOLD suite, version 5.1; Cambridge Crystallographic Data Centre: Cambridge.
44. Stewart, J. J. P. MOPAC 7; Fujitsu Limited: Tokyo, Japan, 1993.
45. StarDrop, version 5.3; Optibrium Ltd: Cambridge, UK.
46. 2A adenosine receptors Life Sci. 1996, 59, 1373-88
47. 2A receptor signalling in striatal cells expressing mutant huntigtin FASEB J. 2001, 5, 1245-1247
48. 3 adenosine receptors Life Sci. 1998, 63, 81-87
49. 2B receptors Biochem. Pharmacol. 2005, 70, 1601-1612
50. Bradford, M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding Anal. Biochem. 1976, 72, 248-254
51. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
52. Munson, P. J.; Rodbard, D. Ligand: a versatile computerized approach for the characterization of ligand binding systems Anal. Biochem. 1980, 107, 220-239
53. McCarthy, K. D. de Vellis, J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue J. Cell. Biol. 1980, 85, 890-902